| Literature DB >> 23219325 |
Albert W Garofalo1, Marc Adler, Danielle L Aubele, Simeon Bowers, Maurizio Franzini, Erich Goldbach, Colin Lorentzen, R Jeffrey Neitz, Gary D Probst, Kevin P Quinn, Pam Santiago, Hing L Sham, Danny Tam, Anh P Truong, Xiaocong M Ye, Zhao Ren.
Abstract
Leucine rich repeat kinase 2 (LRRK2) has been implicated in the pathogenesis of Parkinson's disease (PD). Inhibition of LRRK2 kinase activity is a therapeutic approach that may lead to new treatments for PD. Herein we report the discovery of a series of cinnoline-3-carboxamides that are potent against both wild-type and mutant LRRK2 kinase activity in biochemical assays. These compounds are also shown to be potent inhibitors in a cellular assay and to have good to excellent CNS penetration.Entities:
Mesh：
Substances：
Year: 2012 PMID： 23219325 DOI： 10.1016/j.bmcl.2012.11.021
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823